Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review - Scorecard - MDSpire
Advertisement
Ruxolitinib for Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome: Two Pediatric Cases and Literature Review
Clinical Scorecard: Ruxolitinib Treatment in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: A Review of Two Cases and Relevant Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
Ruxolitinib acts as a Janus kinase (JAK) inhibitor, targeting hyperinflammation. [Source needed]
Target Population
Care Setting
Key Highlights
Ruxolitinib led to marked improvement in systemic hyperinflammation in both cases. [Source needed]
No ruxolitinib-related adverse events were observed in the treated cases. [Source needed]
Guideline-Based Recommendations
Diagnosis
Management
R
u
x
o
l
i
t
i
n
i
b
m
a
y
b
e
u
s
e
d
a
s
a
r
e
s
c
u
e
o
r
b
r
i
d
g
i
n
g
t
h
e
r
a
p
y
f
o
r
r
e
f
r
a
c
t
o
r
y
s
J
I
A
-
M
A
S
.
[
S
o
u
r
c
e
n
e
e
d
e
d
]
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Children aged 1-11 years with refractory sJIA-MAS.
Ruxolitinib combined with other therapies (e.g., glucocorticoids, plasma exchange) showed positive outcomes.
Clinical Best Practices
Consider ruxolitinib for patients unresponsive to first-line therapies. [Source needed]
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
